(Q39211829)

10 September 2017

Risk of pancreatitis in patients treated with incretin-based therapies (English)

1 reference

10 September 2017

0 references

Juris J Meier

1

1 reference

PubMed ID

24723174

10 September 2017

Michael A Nauck

series ordinal

2

1 reference

10 September 2017

11 April 2014

1 reference

10 September 2017

1 reference

10 September 2017

57

1 reference

10 September 2017

7

1 reference

10 September 2017

1320-1324

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-014-3231-y

10 September 2017

0 references

cites work

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3231-Y

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3231-Y

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3231-Y

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3231-Y

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3231-Y

Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3231-Y

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3231-Y

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3231-Y

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3231-Y

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3231-Y

10.1007/S00125-014-3231-Y

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference

PubMed ID

24723174